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Abstract
Background—Calcium intake may reduce risk of colorectal cancer (CRC), but the mechanisms 
remain unclear. Studies of interaction between calcium intake and single nucleotide 
polymorphisms (SNPs) in calcium-related pathways have yielded inconsistent results.
Methods—To identify gene-calcium interactions, we tested interactions between ~2.7 million 
SNPs across the genome with self-reported calcium intake (from dietary or supplemental sources) 
in 9,006 CRC cases and 9,503 controls of European ancestry. To test for multiplicative 
interactions, we used multivariable logistic regression and defined statistical significance using the 
conventional genome-wide α=5E-08.
Results—After accounting for multiple comparisons, there were no statistically significant SNP-
interactions with total, dietary, or supplemental calcium intake.
Conclusions—We found no evidence of SNP-interactions with calcium intake for CRC risk in a 
large population of 18,509 individuals.
Impact—These results suggest that in genome-wide analysis common genetic variants do not 
strongly modify the association between calcium intake and CRC in European populations.
Observational studies suggest higher calcium intake may reduce risk of colorectal cancer 
(CRC) (1, 2); however, the underlying mechanisms remain unclear (2). Gene-environment 
interaction (GxE) analysis can provide insight into disease pathways (3, 4). Studies of gene-
calcium interactions for CRC have focused on single nucleotide polymorphisms (SNPs) in 
calcium-related pathways with limited success (5, 6).
The availability of genome-wide SNP data (7) now enables hypothesis-free GxE searches. 
This method recently identified a novel gene-processed meat interaction for CRC (3)—
highlighting the potential of this approach to provide clues into disease etiology. Here, we 
tested interactions between ~2.7 million SNPs across the genome and calcium intake in 
9,006 CRC cases and 9,503 controls.
MATERIAL AND METHODS
We included 9,006 individuals with confirmed colorectal adenocarcinomas and 9,503 
controls from the Colon Cancer Family Registry (CCFR) and the Genetics and 
Epidemiology of Colorectal Cancer Consortium (GECCO) (3, 4, 7). We excluded 
participants missing all genotype or calcium data, or those of non-European ancestry. 
Participants gave informed written consent and studies were approved by their respective 
Institutional Review Boards.
Genotyping, quality control, and imputation procedures have been described (4, 7). 
Imputation to HapMap CEU was conducted using IMPUTE, BEAGLE, or MACH. In each 
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study, SNPs were restricted based on MAF>20/# samples and imputation accuracy 
(Rsq>0.3). We tested ~2.7 million SNPs.
Data collection/harmonization procedures have been described (3, 4). Calcium intake at the 
reference time was assessed using food frequency questionnaires (FFQs) or diet history 
(DALS); intake (mg/day) was determined from calcium in foods (i.e., dietary) or 
supplements (single+multivitamins+antacids) when available. Total intake was calculated as 
dietary+supplemental calcium. For studies that entered supplement data as regular- vs. non-
user (CCFR, OFCCR, PMH-CCFR), regular use was assigned generic doses (1) of 500 mg/
day, 500 mg/single pill, or 130 mg/multivitamin pill.
Multivariable logistic regression was used to estimate study-specific odds ratios (ORs) and 
95% confidence intervals (CIs) for the association between calcium and CRC risk; study-
specific estimates were combined using fixed-effects meta-analysis. We tested 
multiplicative GxE in each study using SNPxcalcium interaction terms, adjusting for age, 
sex, study center, total energy consumption, first 3 principal components of genetic ancestry, 
and SNP and calcium main effects. This was followed by meta-analysis across studies. 
Statistical significance was determined using the conventional genome-wide 2-sided 
α=5E-08 (3, 7). Heterogeneity was assessed using Woolf's test. We further explored 
interactions using the potentially more powerful Cocktail method (3). Statistical analyses 
used R, Version 2.15.1 or SAS, Version 9.3; power was estimated using Quanto, Version 
1.2.4 (biostats.usc.edu/software).
RESULTS
Higher total calcium intake was associated with reduced CRC risk (OR per quartile=0.87, 
95% CI: 0.84-0.89) (Figure 1A). Dietary and supplemental calcium were similarly 
associated with reduced risk (Figure 1B-C). Total calcium results were similar after 
excluding studies that entered calcium data from only diet (DALS, DACHS, PHS) or 
supplements (CCFR, OFCCR, PMH-CCFR) (OR=0.88, 95% CI: 0.84-0.92). Estimates were 
unchanged for right- vs. left-sided cancers (data not shown). Supporting the validity of our 
calcium data, 2q21.3/MCM6/rs4988235 aka 13910 T>C, a marker of preserved lactase 
levels used in genetic tests of lactose intolerance (8), was associated with dietary 
(P=1.1E-13), but not supplemental (P= 5.2E-01), intake.
There were no statistically significant SNP interactions with total, dietary, or supplemental 
calcium intake for CRC risk (Table 1). The strongest evidence of interaction was between 
4q34.3/rs1028166 and supplemental calcium intake (OR-interaction=1.49, 95% CI: 
1.27-1.74, P-interaction=7.3E-07). However, rs1028166 was located 669-kb from the 
nearest protein-coding gene (TENM3) and showed little evidence of interaction with total or 
dietary intake. The Cocktail approach (3) did not identify statistically significant interactions 
(data not shown).
DISCUSSION
In this large study, there were no statistically significant SNP-interactions with total, dietary, 
or supplemental calcium intake. Candidate-gene studies of interaction between SNPs in 
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calcium-related genes (e.g., CASR, VDR) and calcium intake have not reported consistent 
interactions (5, 6). Figueiredo et al. (2011) (9) investigated genome-wide SNP-calcium 
interactions for microsatellite stable/microsatellite-instability low CRC. Consistent with our 
findings, they reported no statistically significant interactions in 1,191 cases and 990 
controls.
Strengths of this study include the large sample size, comprehensive genetic data, and 
harmonization of calcium intake across 13 studies. However, misclassification of calcium 
intake may have attenuated associations, although calcium assessed by FFQ is reasonably 
accurate compared to diet records/24-hour recalls [correlations=0.48-0.70 (1)], and we 
detected CRC-associations with magnitudes comparable to previous studies (1, 2). For total 
calcium quartiles, at α=5E-08, our study had >80% power to detect interaction ORs ≥1.33, 
1.23, and 1.17 for SNPs with MAFs of 0.05, 0.10, and 0.20, respectively. We thus had 
adequate statistical power to detect modest interactions with common variants.
In summary, we did not observe evidence of SNP-interactions with calcium intake. This 
suggests that individual common genetic variants do not strongly modify the association 
between calcium and CRC risk in European populations. Large studies with sequence data 
are needed to investigate interactions involving rare variants.
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Association between calcium intake and risk of CRC. Estimates correspond to each quartile 
increase in mg/day (total, dietary) or ≥500 vs. <500 mg/day (supplemental). Total and 
dietary calcium intake were coded as sex- and study-specific quartiles based on cut points in 
controls, and modeled as an ordinal variable. Estimates adjusted for age (continuous), sex 
(F/M), study center (indicators), and energy consumption (continuous). Abbreviations: CC, 
case-control; OR, odds ratio; Lower/Upper, lower and upper bounds of 95% confidence 
interval.
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